Wigge Simone, Heißner Klaus, Steger Volker, Ladurner Ruth, Traub Frank, Sipos Bence, Bösmüller Hans, Kanz Lothar, Mayer Frank, Kopp Hans-Georg
Department of Medical Oncology, Hematology, Immunology, Rheumatology and Pulmonology, University of Tübingen, Tübingen, Germany.
Department of Thoracic and Cardiovascular Surgery, University of Tübingen, Tübingen, Germany.
J Surg Oncol. 2018 Jul;118(1):167-176. doi: 10.1002/jso.25115. Epub 2018 Jun 28.
The role of local surgical procedures in patients with metastatic soft tissue sarcoma is still undefined. Few retrospective studies have reported survival benefits for patients with pulmonary metastases after complete surgical resection. Treatment decisions are therefore mainly based on personal experiences rather than on reproducible knowledge.
A total of 237 patients with metastatic sarcoma, treated between 1982 and 2015 at the University Hospital Tuebingen, Germany, were eligible for inclusion. Out of the 237 screened patients, 102 patients underwent at least one metastasectomy. Overall survival was defined as the primary endpoint in this study. For association of non-linear relationship to the endpoint, significant prognostic factors were included into a recursive partitioning model. A subgroup analysis for long-term survivors was also performed.
The median overall survival was 64 months. The 3-, 5-, 10-, and 20-years overall survival rates were 70.7%, 50.3%, 24.7%, and 14.8%, respectively. The number of resections and the progression-free intervals were independent prognostic factors in three statistical models.
Repeated resections of metastases from different localizations are a strong predictor for prolonged survival. We suggest that the progression-free interval after metastasectomy should be considered as a predictive factor for benefit from further surgery.
局部手术在转移性软组织肉瘤患者中的作用仍不明确。少数回顾性研究报道了完全手术切除后肺转移患者的生存获益。因此,治疗决策主要基于个人经验而非可重复的知识。
1982年至2015年期间在德国图宾根大学医院接受治疗的237例转移性肉瘤患者符合纳入标准。在237例筛查患者中,102例患者至少接受了一次转移灶切除术。本研究将总生存期定义为主要终点。为了关联与终点的非线性关系,将显著的预后因素纳入递归划分模型。还对长期生存者进行了亚组分析。
中位总生存期为64个月。3年、5年、10年和20年的总生存率分别为70.7%、50.3%、24.7%和14.8%。在三个统计模型中,切除次数和无进展间期是独立的预后因素。
对不同部位转移灶进行重复切除是延长生存期的有力预测指标。我们建议将转移灶切除术后的无进展间期视为从进一步手术中获益的预测因素。